Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Google is turning its vast public data trove into a goldmine for AI with the debut of the Data Commons Model Context Protocol (MCP) Server — enabling developers, data scientists, and AI agents to ...

In his 1960 book Theory and Design in the First Machine Age, the critic and historian Reyner Banham presciently noted a growing chasm between technological change and the capacity of designers to ...

Post-disaster field observations of the built environment are critical for advancing fundamental research that links hazard data to structural performance, cascading community impacts, and the ...

As artificial intelligence (AI) becomes more integrated into education, ensuring data privacy and security for students and educators is essential. AI-powered tools collect vast amounts of sensitive ...

Forbes contributors publish independent expert analyses and insights. Randy Bean is a noted Senior Advisor, Author, Speaker, Founder, & CEO. How can data and AI be applied to drive business ...

Structure content for AI search so it’s easy for LLMs to cite. Use clarity, formatting, and hierarchy to improve your visibility in AI results. In the SEO world, when we talk about how to structure ...

The application of deep learning algorithms in protein structure prediction has greatly influenced drug discovery and development. Accurate protein structures are crucial for understanding biological ...

Ethio Telecom launched a partnered service with MultiChoice Ethiopia to significantly advance the entertainment sector, enabling customers to access modern fiber broadband internet and mobile data ...

The genetic testing company 23andMe, once a pioneer in consumer DNA testing, has filed for Chapter 11 bankruptcy amid financial struggles, a leadership shakeup and growing concerns about the security ...

Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, ...